I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q3, the actual value is USD 116.74 M.
EPS: As of FY2025 Q3, the actual value is USD -0.27.
EBIT: As of FY2025 Q3, the actual value is USD -2.689 M.
Segment Revenue
- Total revenue for the third quarter of 2025 was $116.7 million, a 52% increase year-over-year.
- Exome and genome test revenue was $98.9 million, representing a 65% increase year-over-year.
Operational Metrics
- Adjusted gross margin expanded to 74%, up from 64% in the third quarter of 2024.
- Adjusted net income was $14.7 million, compared to $2.0 million in the third quarter of 2024.
- GAAP net loss was - $7.6 million.
- Adjusted total operating expenses for Q3 2025 were $71 million.
Cash Flow
- Free cash flow for the third quarter of 2025 was $8.8 million.
- Cash, cash equivalents, marketable securities, and restricted cash totaled $156.1 million as of September 30, 2025.
Unique Metrics
- Exome and genome test volume grew to 25,702, a 33% increase year-over-year.
- Exome and genome tests accounted for 43% of all tests, up from 33% in the third quarter of 2024.
Outlook / Guidance
- GeneDx raised its full-year 2025 revenue guidance to between $425 and $428 million, with expected growth in exome and genome revenue between 53% to 55%.
- The company anticipates an adjusted gross margin of 70% to 71% and positive adjusted net income each quarter and for the full year.